Vir Biotechnology, Inc. (VIR)
11.70
+0.58
(+5.22%)
USD |
NASDAQ |
Oct 09, 16:00
11.49
-0.21
(-1.79%)
After-Hours: 04:57
Vir Biotechnology Enterprise Value : 1.538B for Oct. 9, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 09, 2026 | 1.538B |
| October 08, 2026 | 1.440B |
| October 07, 2026 | 1.508B |
| October 06, 2026 | 1.521B |
| October 05, 2026 | 1.552B |
| October 02, 2026 | 1.448B |
| October 01, 2026 | 1.469B |
| September 30, 2026 | 1.450B |
| September 29, 2026 | 1.360B |
| September 28, 2026 | 1.337B |
| September 25, 2026 | 1.362B |
| September 24, 2026 | 1.372B |
| September 23, 2026 | 1.435B |
| September 22, 2026 | 1.504B |
| September 21, 2026 | 1.399B |
| September 18, 2026 | 1.352B |
| September 17, 2026 | 1.406B |
| September 16, 2026 | 1.338B |
| September 15, 2026 | 1.325B |
| September 14, 2026 | 1.380B |
| September 11, 2026 | 1.355B |
| September 10, 2026 | 1.349B |
| September 09, 2026 | 1.388B |
| September 08, 2026 | 1.450B |
| September 04, 2026 | 1.485B |
| Date | Value |
|---|---|
| September 03, 2026 | 1.496B |
| September 02, 2026 | 1.504B |
| September 01, 2026 | 1.526B |
| August 31, 2026 | 1.410B |
| August 28, 2026 | 1.391B |
| August 27, 2026 | 1.472B |
| August 26, 2026 | 1.433B |
| August 25, 2026 | 1.371B |
| August 24, 2026 | 1.235B |
| August 21, 2026 | 1.213B |
| August 20, 2026 | 1.117B |
| August 19, 2026 | 1.212B |
| August 18, 2026 | 1.164B |
| August 17, 2026 | 1.147B |
| August 14, 2026 | 1.122B |
| August 13, 2026 | 1.081B |
| August 12, 2026 | 1.075B |
| August 11, 2026 | 1.069B |
| August 10, 2026 | 1.063B |
| August 07, 2026 | 1.051B |
| August 06, 2026 | 1.042B |
| August 05, 2026 | 1.100B |
| August 04, 2026 | 1.110B |
| August 03, 2026 | 1.064B |
| July 31, 2026 | 1.024B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Moderna, Inc. | 85.92B |
| Vaxcyte, Inc. | 8.963B |
| Caribou Biosciences, Inc. | -36.88M |
| Arrowhead Pharmaceuticals, Inc. | 8.631B |
| Oncolytics Biotech, Inc. | 65.76M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 80.08M |
| Revenue (Quarterly) | 238.95M |
| Total Expenses (Quarterly) | 158.87M |
| EPS Diluted (Quarterly) | 0.4742 |
| Gross Profit Margin (Quarterly) | 98.83% |
| Profit Margin (Quarterly) | 33.51% |
| Earnings Yield | -15.91% |
| Normalized Earnings Yield | -15.76 |